Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Change in Accured Expenses (2018 - 2022)

Rapid Therapeutic Science Laboratories' Change in Accured Expenses history spans 6 years, with the latest figure at $14898.0 for Q2 2023.

  • For Q2 2023, Change in Accured Expenses fell 86.76% year-over-year to $14898.0; the TTM value through Jun 2023 reached -$116840.0, down 146.34%, while the annual FY2022 figure was $79040.0, 221.67% up from the prior year.
  • Change in Accured Expenses for Q2 2023 was $14898.0 at Rapid Therapeutic Science Laboratories, down from $33880.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $132121.0 in Q1 2022 and bottomed at -$244658.0 in Q3 2022.
  • The 5-year median for Change in Accured Expenses is $23586.5 (2020), against an average of $17312.1.
  • The largest YoY upside for Change in Accured Expenses was 3300.94% in 2022 against a maximum downside of 1330.16% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $127689.0 in 2019, then fell by 23.5% to $97685.0 in 2020, then crashed by 74.85% to $24572.0 in 2021, then soared by 221.67% to $79040.0 in 2022, then tumbled by 81.15% to $14898.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Change in Accured Expenses are $14898.0 (Q2 2023), $33880.0 (Q1 2023), and $79040.0 (Q4 2022).